160.05
+1.95(+1.23%)
Currency In USD
| Previous Close | 158.1 |
| Open | 157.97 |
| Day High | 161.79 |
| Day Low | 156.71 |
| 52-Week High | 183 |
| 52-Week Low | 111.09 |
| Volume | 338,329 |
| Average Volume | 507,803 |
| Market Cap | 9.66B |
| PE | -24.51 |
| EPS | -6.53 |
| Moving Average 50 Days | 157.94 |
| Moving Average 200 Days | 140.14 |
| Change | 1.95 |
If you invested $1000 in Ascendis Pharma A/S (ASND) 10 years ago, it would be worth $9,246.1 as of May 23, 2025 at a share price of $160.05. Whereas If you bought $1000 worth of Ascendis Pharma A/S (ASND) shares 5 years ago, it would be worth $1,095.41 as of May 23, 2025 at a share price of $160.05.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
New Data Shows Improvements in Growth and Bone Morphometry in Children with Achondroplasia Treated with TransCon® CNP (Navepegritide)
GlobeNewswire Inc.
May 13, 2025 8:01 PM GMT
COPENHAGEN, Denmark, May 13, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced new data showing improvements in growth and bone morphometry from Week 52 of its pivotal ApproaCH Trial of TransCon CNP (navepegritide) in chil
New 4-Year Data Shows Sustained Response to TransCon® PTH (Palopegteriparatide) Therapy in Adults with Hypoparathyroidism
GlobeNewswire Inc.
May 12, 2025 8:45 PM GMT
COPENHAGEN, Denmark, May 12, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced new data from Week 214 of its Phase 2 PaTH Forward Trial showing that long-term treatment with TransCon PTH (palopegteriparatide) continued to
Ascendis to Share Its Latest Endocrinology Rare Disease Data at ESPE & ESE 2025
GlobeNewswire Inc.
May 05, 2025 12:30 PM GMT
COPENHAGEN, Denmark, May 05, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it will share the latest data from its hypoparathyroidism, achondroplasia, and growth hormone deficiency (GHD) programs during ESPE & ESE 2025,